Caribou Biosciences Inc（CRBU）資訊與事件CRBUCaribou Biosciences Inc

Caribou Reports Q2 Revenue of $1.5M, Below Expectations

Reports Q2 revenue $1.5M, consensus $2.25M. "At Caribou, we are redefining what patients and physicians should expect from allogeneic CAR-T cell therapy," said Rachel Haurwitz, president and CEO of Caribou. "The data presented at EHA 2026 continue to demonstrate that a single dose of vispa-cel can produce durable responses on par with autologous CAR-T cell therapies in patients with second-line large B cell lymphoma, and a single dose of CB-011 results in deep, durable responses in high-risk patients with relapsed or refractory multiple myeloma. With our off-the-shelf approach, these programs have the potential to dramatically expand CAR-T cell therapy access for patients."

Caribou Biosciences Reports Significant Efficacy of vispa-cel CAR-T Therapy

Caribou Biosciences announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma, with the potential to bring the benefit of cell therapy to patients who lack curative options. The results are being presented during an oral presentation at the 2026 European Hematology Association annual meeting on June 12 at 5:15pm CEST, in Stockholm, Sweden. As of the March 6, data cutoff date, 27 second-line large B cell lymphoma patients had received a single dose of 80M optimized vispa-cel CAR-T cells, defined as cells from a donor younger than 30 years old with at least two matched human leukocyte antigen alleles between patient and donor. This pivotal optimized vispa-cel subgroup best represents the treatment regimen and patient population for the planned ANTLER-3 phase 3 clinical trial. Efficacy data from the pivotal optimized vispa-cel subgroup included: 82% overall response rate, 67% complete response rate and 17.1 months median progression-free survival. Vispa-cel continues to demonstrate a generally well-tolerated safety profile. In the pivotal optimized vispa-cel subgroup, there were no reports of graft-versus-host disease or grade 3 or higher immune effector cell-associated neurotoxicity syndrome, and there was one greater than or equal toGr 3 cytokine release syndrome. Other adverse events of special interest included six greater than or equal toGr 3 infections, five greater than or equal to Gr 3 prolonged cytopenias, and one greater than or equal to Gr 3 immune effector cell-associated HLH-like syndrome. In the pivotal optimized vispa-cel subgroup, one vispa-cel-related death occurred due to IEC-HS and one possibly-related death occurred due to progressive multifocal leukoencephalopathy.